CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Metformin +2 moredrug
Likely dose
Metformin 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01427595
NCT01427595N/ACompleted

Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)

University of Virginia·interventional·Posted Sep 1, 2011·Updated Jan 8, 2021

In Brief

A clinical study evaluating Metformin, Progesterone, and 1 other intervention for Polycystic Ovary Syndrome and Hyperandrogenism. Completed, enrolled 25 participants across 1 site.

Detailed Summary

Many, but not all, girls with high levels of the male hormone testosterone go on to develop polycystic ovary syndrome (PCOS) as adults. Women with PCOS often have irregular menstrual periods, excess facial and body hair, and weight gain. PCOS is also a leading cause of difficulty becoming pregnant. The investigators do not understand why some girls with high hormones develop PCOS and others do not. In a previous study by our group, some girls with high levels of male hormones had abnormalities in the secretion of another hormone, called luteinizing hormone (LH), that are often seen in women with PCOS. However, another group had normal LH secretion. The girls with the abnormal LH secretion had higher levels of another hormone, called insulin, than the girls with normal LH secretion. The investigators will test whether metformin, an insulin-sensitizing agent, changes the effects of high male hormone levels in adolescent girls, specifically by looking at their LH secretion response following metformin treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 1, 2011
Enrollment StartFeb 18, 2009
Primary CompletionJan 17, 2015
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 14.8 years ago

Interventions

Metformindrug

500-2000 mg PO BID (X12 weeks)

Progesteronedrug

oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)

estracedrug

oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2